ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Opioid-Induced Constipation Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Published Date: July 2025
|
Report Code: QYRE-Auto-716
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Opioid Induced Constipation Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
BUY CHAPTERS

Global Opioid-Induced Constipation Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-716
Report
July 2025
Pages:155
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
Mallinckrodt plc
ch Health)
Astrazeneca plc
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Salix
Takeda Pharmaceutical
Takeda Pharmaceuticals
Bayer
Salix (Bausch Health)

Opioid-Induced Constipation Market Size

In 2024, the global market size of Opioid-Induced Constipation was estimated to be worth US$ 2767 million and is forecast to reach approximately US$ 3775 million by 2031 with a CAGR of 4.6% during the forecast period 2025-2031.

Opioid-Induced Constipation Market

Opioid-Induced Constipation Market

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Opioid-Induced Constipation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid-Induced Constipation.
The Opioid-Induced Constipation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Opioid-Induced Constipation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opioid-Induced Constipation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.

Scope of Opioid-Induced Constipation Market Report

Report Metric Details
Report Name Opioid-Induced Constipation Market
CAGR 4.6%
Segment by Type
  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Others
Segment by Application
  • Hospital
  • Pharmacy
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Sales (consumption), revenue of Opioid-Induced Constipation in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
  • Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Opioid-Induced Constipation sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
  • Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
  • Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
  • Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 14: Research Findings and Conclusion.

FAQ for this report

What is the market share of major companies in Opioid-Induced Constipation Market?

Ans: Global top three manufacturers hold a share over 45%.

What is the Opioid-Induced Constipation Market share by type?

Ans: In terms of product, Lubiprostone is the largest segment, with a share about 5%.

Who are the main players in the Opioid-Induced Constipation Market report?

Ans: The main players in the Opioid-Induced Constipation Market are Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi

What are the Application segmentation covered in the Opioid-Induced Constipation Market report?

Ans: The Applications covered in the Opioid-Induced Constipation Market report are Hospital, Pharmacy, Other

What are the Type segmentation covered in the Opioid-Induced Constipation Market report?

Ans: The Types covered in the Opioid-Induced Constipation Market report are Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others

1 Study Coverage
1.1 Opioid-Induced Constipation Product Introduction
1.2 Market by Type
1.2.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Market by Application
1.3.1 Global Opioid-Induced Constipation Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
2.1.1 Global Opioid-Induced Constipation Revenue 2020-2031
2.1.2 Global Opioid-Induced Constipation Sales 2020-2031
2.2 Opioid-Induced Constipation Market Size by Region: 2024 Versus 2031
2.3 Opioid-Induced Constipation Sales by Region (2020-2031)
2.3.1 Global Opioid-Induced Constipation Sales by Region: 2020-2025
2.3.2 Global Opioid-Induced Constipation Sales Forecast by Region (2026-2031)
2.3.3 Global Opioid-Induced Constipation Sales Market Share by Region (2020-2031)
2.4 Opioid-Induced Constipation Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Opioid-Induced Constipation Revenue by Region: 2020-2025
2.4.2 Global Opioid-Induced Constipation Revenue Forecast by Region (2026-2031)
2.4.3 Global Opioid-Induced Constipation Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Opioid-Induced Constipation Sales by Type (2020-2031)
3.1.1.1 Global Opioid-Induced Constipation Sales Volume by Type (2020-2031)
3.1.1.2 Global Opioid-Induced Constipation Sales Market Share by Type (2020-2031)
3.1.2 Global Opioid-Induced Constipation Revenue by Type (2020-2031)
3.1.2.1 Global Opioid-Induced Constipation Revenue by Type (2020-2031)
3.1.2.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2020-2031)
3.1.3 Opioid-Induced Constipation Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Opioid-Induced Constipation Sales by Application (2020-2031)
3.2.1.1 Global Opioid-Induced Constipation Sales Volume by Application (2020-2031)
3.2.1.2 Global Opioid-Induced Constipation Sales Market Share by Application (2020-2031)
3.2.2 Global Opioid-Induced Constipation Revenue by Application (2020-2031)
3.2.2.1 Global Opioid-Induced Constipation Revenue by Application (2020-2031)
3.2.2.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2020-2031)
3.2.3 Opioid-Induced Constipation Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Methylnaltrexone Bromide of Opioid-Induced Constipation Revenue Market Share by Application
3.3.2 Lubiprostone of Opioid-Induced Constipation Revenue Market Share by Application
3.3.3 Naloxegol of Opioid-Induced Constipation Revenue Market Share by Application
3.3.4 Others of Opioid-Induced Constipation Revenue Market Share by Application
4 Global Opioid-Induced Constipation by Manufacturers
4.1 Global Top Opioid-Induced Constipation Manufacturers by Sales (2020-2025)
4.1.1 Global Opioid-Induced Constipation Sales by Manufacturer (2020-2025)
4.1.2 Global Opioid-Induced Constipation Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Opioid-Induced Constipation Manufacturers by Revenue (2020-2025)
4.2.1 Global Opioid-Induced Constipation Revenue by Manufacturer (2020-2025)
4.2.2 Global Opioid-Induced Constipation Revenue Share by Manufacturer (2020-2025)
4.3 Global Opioid-Induced Constipation Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Opioid-Induced Constipation Manufacturers Covered: Ranking by Revenue
4.4.2 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Opioid-Induced Constipation Manufacturing Base Distribution, Product Type
4.5.1 Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Opioid-Induced Constipation Market
4.5.3 Manufacturers Opioid-Induced Constipation Product Type and Application
4.5.4 Methylnaltrexone Bromide Market Sales of Opioid-Induced Constipation by Manufacturer
4.5.5 Lubiprostone Market Sales of Opioid-Induced Constipation by Manufacturer
4.5.6 Naloxegol Market Sales of Opioid-Induced Constipation by Manufacturer
4.5.7 Others Market Sales of Opioid-Induced Constipation by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Takeda Pharmaceuticals
5.1.1 Takeda Pharmaceuticals Company Information
5.1.2 Takeda Pharmaceuticals Description, Business Overview
5.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
5.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Takeda Pharmaceuticals Opioid-Induced Constipation Sales by Product in 2024
5.1.6 Takeda Pharmaceuticals Opioid-Induced Constipation Sales by Application in 2024
5.1.7 Takeda Pharmaceuticals Opioid-Induced Constipation Sales by Geographic Area in 2024
5.1.8 Takeda Pharmaceuticals Recent Developments
5.2 Bayer
5.2.1 Bayer Company Information
5.2.2 Bayer Description, Business Overview
5.2.3 Bayer Opioid-Induced Constipation Products Offered
5.2.4 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Bayer Opioid-Induced Constipation Sales by Product in 2024
5.2.6 Bayer Opioid-Induced Constipation Sales by Application in 2024
5.2.7 Bayer Opioid-Induced Constipation Sales by Geographic Area in 2024
5.2.8 Bayer Recent Developments
5.3 Sanofi
5.3.1 Sanofi Company Information
5.3.2 Sanofi Description, Business Overview
5.3.3 Sanofi Opioid-Induced Constipation Products Offered
5.3.4 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Sanofi Opioid-Induced Constipation Sales by Product in 2024
5.3.6 Sanofi Opioid-Induced Constipation Sales by Application in 2024
5.3.7 Sanofi Opioid-Induced Constipation Sales by Geographic Area in 2024
5.3.8 Sanofi Recent Developments
5.4 Mallinckrodt
5.4.1 Mallinckrodt Company Information
5.4.2 Mallinckrodt Description, Business Overview
5.4.3 Mallinckrodt Opioid-Induced Constipation Products Offered
5.4.4 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Mallinckrodt Opioid-Induced Constipation Sales by Product in 2024
5.4.6 Mallinckrodt Opioid-Induced Constipation Sales by Application in 2024
5.4.7 Mallinckrodt Opioid-Induced Constipation Sales by Geographic Area in 2024
5.4.8 Mallinckrodt Recent Developments
5.5 Salix (Bausch Health)
5.5.1 Salix (Bausch Health) Company Information
5.5.2 Salix (Bausch Health) Description, Business Overview
5.5.3 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
5.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Salix (Bausch Health) Opioid-Induced Constipation Sales by Product in 2024
5.5.6 Salix (Bausch Health) Opioid-Induced Constipation Sales by Application in 2024
5.5.7 Salix (Bausch Health) Opioid-Induced Constipation Sales by Geographic Area in 2024
5.5.8 Salix (Bausch Health) Recent Developments
5.6 AstraZeneca
5.6.1 AstraZeneca Company Information
5.6.2 AstraZeneca Description, Business Overview
5.6.3 AstraZeneca Opioid-Induced Constipation Products Offered
5.6.4 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.6.5 AstraZeneca Opioid-Induced Constipation Sales by Product in 2024
5.6.6 AstraZeneca Opioid-Induced Constipation Sales by Application in 2024
5.6.7 AstraZeneca Opioid-Induced Constipation Sales by Geographic Area in 2024
5.6.8 AstraZeneca Recent Developments
5.7 Progenics Pharmaceuticals
5.7.1 Progenics Pharmaceuticals Company Information
5.7.2 Progenics Pharmaceuticals Description, Business Overview
5.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
5.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Progenics Pharmaceuticals Opioid-Induced Constipation Sales by Product in 2024
5.7.6 Progenics Pharmaceuticals Opioid-Induced Constipation Sales by Application in 2024
5.7.7 Progenics Pharmaceuticals Opioid-Induced Constipation Sales by Geographic Area in 2024
5.7.8 Progenics Pharmaceuticals Recent Developments
5.8 Purdue Pharm
5.8.1 Purdue Pharm Company Information
5.8.2 Purdue Pharm Description, Business Overview
5.8.3 Purdue Pharm Opioid-Induced Constipation Products Offered
5.8.4 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.8.5 Purdue Pharm Opioid-Induced Constipation Sales by Product in 2024
5.8.6 Purdue Pharm Opioid-Induced Constipation Sales by Application in 2024
5.8.7 Purdue Pharm Opioid-Induced Constipation Sales by Geographic Area in 2024
5.8.8 Purdue Pharm Recent Developments
5.9 Nektar Therapeutics
5.9.1 Nektar Therapeutics Company Information
5.9.2 Nektar Therapeutics Description, Business Overview
5.9.3 Nektar Therapeutics Opioid-Induced Constipation Products Offered
5.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.9.5 Nektar Therapeutics Opioid-Induced Constipation Sales by Product in 2024
5.9.6 Nektar Therapeutics Opioid-Induced Constipation Sales by Application in 2024
5.9.7 Nektar Therapeutics Opioid-Induced Constipation Sales by Geographic Area in 2024
5.9.8 Nektar Therapeutics Recent Developments
5.10 Daiichi Sankyo
5.10.1 Daiichi Sankyo Company Information
5.10.2 Daiichi Sankyo Description, Business Overview
5.10.3 Daiichi Sankyo Opioid-Induced Constipation Products Offered
5.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Daiichi Sankyo Opioid-Induced Constipation Sales by Product in 2024
5.10.6 Daiichi Sankyo Opioid-Induced Constipation Sales by Application in 2024
5.10.7 Daiichi Sankyo Opioid-Induced Constipation Sales by Geographic Area in 2024
5.10.8 Daiichi Sankyo Recent Developments
5.11 Prestige
5.11.1 Prestige Company Information
5.11.2 Prestige Description, Business Overview
5.11.3 Prestige Opioid-Induced Constipation Products Offered
5.11.4 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.11.5 Prestige Opioid-Induced Constipation Sales by Product in 2024
5.11.6 Prestige Opioid-Induced Constipation Sales by Application in 2024
5.11.7 Prestige Opioid-Induced Constipation Sales by Geographic Area in 2024
5.11.8 Prestige Recent Developments
5.12 GSK
5.12.1 GSK Company Information
5.12.2 GSK Description, Business Overview
5.12.3 GSK Opioid-Induced Constipation Products Offered
5.12.4 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.12.5 GSK Opioid-Induced Constipation Sales by Product in 2024
5.12.6 GSK Opioid-Induced Constipation Sales by Application in 2024
5.12.7 GSK Opioid-Induced Constipation Sales by Geographic Area in 2024
5.12.8 GSK Recent Developments
5.13 Shionogi
5.13.1 Shionogi Company Information
5.13.2 Shionogi Description, Business Overview
5.13.3 Shionogi Opioid-Induced Constipation Products Offered
5.13.4 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2020-2025)
5.13.5 Shionogi Opioid-Induced Constipation Sales by Product in 2024
5.13.6 Shionogi Opioid-Induced Constipation Sales by Application in 2024
5.13.7 Shionogi Opioid-Induced Constipation Sales by Geographic Area in 2024
5.13.8 Shionogi Recent Developments
6 North America
6.1 North America Opioid-Induced Constipation Market Size YoY Growth 2020-2031
6.2 North America Opioid-Induced Constipation Market Facts & Figures by Country
6.2.1 North America Opioid-Induced Constipation Sales by Country (2020-2031)
6.2.2 North America Opioid-Induced Constipation Revenue by Country (2020-2031)
6.3 North America Opioid-Induced Constipation Sales by Type (2020-2025)
6.4 North America Opioid-Induced Constipation Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Opioid-Induced Constipation Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Opioid-Induced Constipation Market Facts & Figures by Region
7.2.1 Asia-Pacific Opioid-Induced Constipation Sales by Region (2020-2031)
7.2.2 Asia-Pacific Opioid-Induced Constipation Revenue by Region (2020-2031)
7.3 Asia-Pacific Opioid-Induced Constipation Sales by Type (2020-2025)
7.4 Asia-Pacific Opioid-Induced Constipation Sales by Application (2020-2025)
8 Europe
8.1 Europe Opioid-Induced Constipation Market Size YoY Growth 2020-2031
8.2 Europe Opioid-Induced Constipation Market Facts & Figures by Country
8.2.1 Europe Opioid-Induced Constipation Sales by Country (2020-2031)
8.2.2 Europe Opioid-Induced Constipation Revenue by Country (2020-2031)
8.3 Europe Opioid-Induced Constipation Sales by Type (2020-2025)
8.4 Europe Opioid-Induced Constipation Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Opioid-Induced Constipation Market Size YoY Growth 2020-2031
9.2 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
9.2.1 Latin America Opioid-Induced Constipation Sales by Country (2020-2031)
9.2.2 Latin America Opioid-Induced Constipation Revenue by Country (2020-2031)
9.3 Latin America Opioid-Induced Constipation Sales by Type (2020-2025)
9.4 Latin America Opioid-Induced Constipation Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Opioid-Induced Constipation Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
10.2.1 Middle East and Africa Opioid-Induced Constipation Sales by Country (2020-2031)
10.2.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2020-2031)
10.3 Middle East and Africa Opioid-Induced Constipation Sales by Type (2020-2025)
10.4 Middle East and Africa Opioid-Induced Constipation Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Opioid-Induced Constipation Supply Chain Analysis
11.2 Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers
11.3 Opioid-Induced Constipation Clients Analysis
11.4 Opioid-Induced Constipation Sales Channel and Sales Model Analysis
11.4.1 Opioid-Induced Constipation Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Opioid-Induced Constipation Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Opioid-Induced Constipation Distributors
12 Opioid-Induced Constipation Market Dynamics
12.1 Opioid-Induced Constipation Industry Trends
12.2 Opioid-Induced Constipation Market Drivers
12.3 Opioid-Induced Constipation Market Challenges
12.4 Opioid-Induced Constipation Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
FEATURED COMPANIES
Sanofi
Mallinckrodt plc
ch Health)
Astrazeneca plc
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Salix
Takeda Pharmaceutical
Takeda Pharmaceuticals
Bayer
Salix (Bausch Health)
List of Tables
 Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Opioid-Induced Constipation Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2024 VS 2031
 Table 4. Global Opioid-Induced Constipation Sales by Region (2020-2025) & (K Units)
 Table 5. Global Opioid-Induced Constipation Sales Forecast by Region (2026-2031) & (K Units)
 Table 6. Global Opioid-Induced Constipation Revenue by Region (2020-2025) & (US$ Million)
 Table 7. Global Opioid-Induced Constipation Revenue Forecast by Region (2026-2031) & (US$ Million)
 Table 8. Global Opioid-Induced Constipation Sales Volume by Type (2020-2025) & (K Units)
 Table 9. Global Opioid-Induced Constipation Sales Volume by Type (2026-2031) & (K Units)
 Table 10. Global Opioid-Induced Constipation Revenue by Type (2020-2025) & (US$ Million)
 Table 11. Global Opioid-Induced Constipation Revenue Forecast by Type (2026-2031) & (US$ Million)
 Table 12. Global Opioid-Induced Constipation Sales Volume by Application (2020-2025) & (K Units)
 Table 13. Global Opioid-Induced Constipation Sales Volume by Application (2026-2031) & (K Units)
 Table 14. Global Opioid-Induced Constipation Revenue by Application (2020-2025) & (US$ Million)
 Table 15. Global Opioid-Induced Constipation Revenue by Application (2026-2031) & (US$ Million)
 Table 16. Global Opioid-Induced Constipation Sales by Manufacturer (2020-2025) & (K Units)
 Table 17. Global Opioid-Induced Constipation Sales Share by Manufacturer (2020-2025)
 Table 18. Opioid-Induced Constipation Revenue by Manufacturer (2020-2025) & (US$ Million)
 Table 19. Opioid-Induced Constipation Revenue Share by Manufacturer (2020-2025)
 Table 20. Key Manufacturers Opioid-Induced Constipation Price (2020-2025) & (USD/Unit)
 Table 21. Ranking of Global Top Opioid-Induced Constipation Manufacturers by Revenue (US$ Million) in 2024
 Table 22. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
 Table 23. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2024)
 Table 24. Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution and Headquarters
 Table 25. Date of International Manufacturers Enter into Opioid-Induced Constipation Market
 Table 26. Manufacturers Opioid-Induced Constipation Product Type and Application
 Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 28. Takeda Pharmaceuticals Company Information
 Table 29. Takeda Pharmaceuticals Description and Business Overview
 Table 30. Takeda Pharmaceuticals Opioid-Induced Constipation Product
 Table 31. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 32. Takeda Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 33. Takeda Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 34. Takeda Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 35. Takeda Pharmaceuticals Recent Developments
 Table 36. Bayer Company Information
 Table 37. Bayer Description and Business Overview
 Table 38. Bayer Opioid-Induced Constipation Product
 Table 39. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 40. Bayer Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 41. Bayer Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 42. Bayer Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 43. Bayer Recent Developments
 Table 44. Sanofi Company Information
 Table 45. Sanofi Description and Business Overview
 Table 46. Sanofi Opioid-Induced Constipation Product
 Table 47. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 48. Sanofi Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 49. Sanofi Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 50. Sanofi Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 51. Sanofi Recent Developments
 Table 52. Mallinckrodt Company Information
 Table 53. Mallinckrodt Description and Business Overview
 Table 54. Mallinckrodt Opioid-Induced Constipation Product
 Table 55. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 56. Mallinckrodt Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 57. Mallinckrodt Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 58. Mallinckrodt Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 59. Mallinckrodt Recent Developments
 Table 60. Salix (Bausch Health) Company Information
 Table 61. Salix (Bausch Health) Description and Business Overview
 Table 62. Salix (Bausch Health) Opioid-Induced Constipation Product
 Table 63. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 64. Salix (Bausch Health) Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 65. Salix (Bausch Health) Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 66. Salix (Bausch Health) Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 67. Salix (Bausch Health) Recent Developments
 Table 68. AstraZeneca Company Information
 Table 69. AstraZeneca Description and Business Overview
 Table 70. AstraZeneca Opioid-Induced Constipation Product
 Table 71. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 72. AstraZeneca Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 73. AstraZeneca Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 74. AstraZeneca Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 75. AstraZeneca Recent Developments
 Table 76. Progenics Pharmaceuticals Company Information
 Table 77. Progenics Pharmaceuticals Description and Business Overview
 Table 78. Progenics Pharmaceuticals Opioid-Induced Constipation Product
 Table 79. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 80. Progenics Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 81. Progenics Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 82. Progenics Pharmaceuticals Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 83. Progenics Pharmaceuticals Recent Developments
 Table 84. Purdue Pharm Company Information
 Table 85. Purdue Pharm Description and Business Overview
 Table 86. Purdue Pharm Opioid-Induced Constipation Product
 Table 87. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Purdue Pharm Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 89. Purdue Pharm Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 90. Purdue Pharm Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 91. Purdue Pharm Recent Developments
 Table 92. Nektar Therapeutics Company Information
 Table 93. Nektar Therapeutics Description and Business Overview
 Table 94. Nektar Therapeutics Opioid-Induced Constipation Product
 Table 95. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 96. Nektar Therapeutics Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 97. Nektar Therapeutics Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 98. Nektar Therapeutics Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 99. Nektar Therapeutics Recent Developments
 Table 100. Daiichi Sankyo Company Information
 Table 101. Daiichi Sankyo Description and Business Overview
 Table 102. Daiichi Sankyo Opioid-Induced Constipation Product
 Table 103. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 104. Daiichi Sankyo Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 105. Daiichi Sankyo Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 106. Daiichi Sankyo Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 107. Daiichi Sankyo Recent Developments
 Table 108. Prestige Company Information
 Table 109. Prestige Description and Business Overview
 Table 110. Prestige Opioid-Induced Constipation Product
 Table 111. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 112. Prestige Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 113. Prestige Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 114. Prestige Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 115. Prestige Recent Developments
 Table 116. GSK Company Information
 Table 117. GSK Description and Business Overview
 Table 118. GSK Opioid-Induced Constipation Product
 Table 119. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 120. GSK Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 121. GSK Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 122. GSK Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 123. GSK Recent Developments
 Table 124. Shionogi Company Information
 Table 125. Shionogi Description and Business Overview
 Table 126. Shionogi Opioid-Induced Constipation Product
 Table 127. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Shionogi Sales Proportion of Opioid-Induced Constipation by Product in 2024
 Table 129. Shionogi Sales Proportion of Opioid-Induced Constipation by Application in 2024
 Table 130. Shionogi Sales Proportion of Opioid-Induced Constipation by Geographic Area in 2024
 Table 131. Shionogi Recent Developments
 Table 132. North America Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
 Table 133. North America Opioid-Induced Constipation Sales by Country (2026-2031) & (K Units)
 Table 134. North America Opioid-Induced Constipation Revenue by Country (2020-2025) & (US$ Million)
 Table 135. North America Opioid-Induced Constipation Revenue by Country (2026-2031) & (US$ Million)
 Table 136. North America Opioid-Induced Constipation Sales by Type (2020-2025) & (K Units)
 Table 137. North America Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
 Table 138. Asia-Pacific Opioid-Induced Constipation Sales by Region (2020-2025) & (K Units)
 Table 139. Asia-Pacific Opioid-Induced Constipation Sales by Region (2026-2031) & (K Units)
 Table 140. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2020-2025) & (US$ Million)
 Table 141. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2026-2031) & (US$ Million)
 Table 142. Asia-Pacific Opioid-Induced Constipation Sales by Type (2020-2025) & (K Units)
 Table 143. Asia-Pacific Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
 Table 144. Europe Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
 Table 145. Europe Opioid-Induced Constipation Sales by Country (2026-2031) & (K Units)
 Table 146. Europe Opioid-Induced Constipation Revenue by Country (2020-2025) & (US$ Million)
 Table 147. Europe Opioid-Induced Constipation Revenue by Country (2026-2031) & (US$ Million)
 Table 148. Europe Opioid-Induced Constipation Sales by Type (2020-2025) & (K Units)
 Table 149. Europe Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
 Table 150. Latin America Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
 Table 151. Latin America Opioid-Induced Constipation Sales by Country (2026-2031) & (K Units)
 Table 152. Latin America Opioid-Induced Constipation Revenue by Country (2020-2025) & (US$ Million)
 Table 153. Latin America Opioid-Induced Constipation Revenue by Country (2026-2031) & (US$ Million)
 Table 154. Latin America Opioid-Induced Constipation Sales by Type (2020-2025) & (K Units)
 Table 155. Latin America Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
 Table 156. Middle East and Africa Opioid-Induced Constipation Sales by Country (2020-2025) & (K Units)
 Table 157. Middle East and Africa Opioid-Induced Constipation Sales by Country (2026-2031) & (K Units)
 Table 158. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2020-2025) & (US$ Million)
 Table 159. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2026-2031) & (US$ Million)
 Table 160. Middle East and Africa Opioid-Induced Constipation Sales by Type (2020-2025) & (K Units)
 Table 161. Middle East and Africa Opioid-Induced Constipation Sales by Application (2020-2025) & (K Units)
 Table 162. Opioid-Induced Constipation Key Raw Materials, Industry Status and Trend
 Table 163. Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers
 Table 164. Opioid-Induced Constipation Clients Status and Trend
 Table 165. Opioid-Induced Constipation Typical Clients
 Table 166. Opioid-Induced Constipation Distributors
 Table 167. Opioid-Induced Constipation Market Trends
 Table 168. Opioid-Induced Constipation Market Drivers
 Table 169. Opioid-Induced Constipation Market Challenges
 Table 170. Opioid-Induced Constipation Market Restraints
 Table 171. Research Programs/Design for This Report
 Table 172. Key Data Information from Secondary Sources
 Table 173. Key Data Information from Primary Sources
 Table 174. QYR Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Opioid-Induced Constipation Product Picture
 Figure 2. Global Opioid-Induced Constipation Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
 Figure 3. Global Opioid-Induced Constipation Sales Market Share by Type in 2024 & 2031
 Figure 4. Methylnaltrexone Bromide Product Picture
 Figure 5. Lubiprostone Product Picture
 Figure 6. Naloxegol Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Opioid-Induced Constipation Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
 Figure 9. Global Opioid-Induced Constipation Sales Market Share by Application in 2024 & 2031
 Figure 10. Hospital
 Figure 11. Pharmacy
 Figure 12. Other
 Figure 13. Opioid-Induced Constipation Report Years Considered
 Figure 14. Global Opioid-Induced Constipation Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Opioid-Induced Constipation Market Size 2020-2031 (US$ Million)
 Figure 16. Global Opioid-Induced Constipation Sales 2020-2031 (K Units)
 Figure 17. Global Opioid-Induced Constipation Sales Market Share Forecast by Region (2020-2031)
 Figure 18. Global Opioid-Induced Constipation Revenue Market Share by Region (2020-2031)
 Figure 19. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2020-2031)
 Figure 20. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2020-2031)
 Figure 21. Opioid-Induced Constipation Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
 Figure 22. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2020-2031)
 Figure 23. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2020-2031)
 Figure 24. Opioid-Induced Constipation Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
 Figure 25. Methylnaltrexone Bromide of Opioid-Induced Constipation Revenue Market Share by Application, 2024 VS 2031
 Figure 26. Lubiprostone of Opioid-Induced Constipation Revenue Market Share by Application, 2024 VS 2031
 Figure 27. Naloxegol of Opioid-Induced Constipation Revenue Market Share by Application, 2024 VS 2031
 Figure 28. Others of Opioid-Induced Constipation Revenue Market Share by Application, 2024 VS 2031
 Figure 29. Global Opioid-Induced Constipation Sales Share by Manufacturer in 2024
 Figure 30. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 31. Methylnaltrexone Bromide Market Sales Proportion by Manufacturer in 2024
 Figure 32. Lubiprostone Market Sales Proportion by Manufacturer in 2024
 Figure 33. Naloxegol Market Sales Proportion by Manufacturer in 2024
 Figure 34. Others Market Sales Proportion by Manufacturer in 2024
 Figure 35. North America Opioid-Induced Constipation Revenue 2020-2031 (US$ Million)
 Figure 36. North America Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
 Figure 37. North America Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
 Figure 38. Asia-Pacific Opioid-Induced Constipation Revenue 2020-2031 (US$ Million)
 Figure 39. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Region (2020-2031)
 Figure 40. Asia-Pacific Opioid-Induced Constipation Revenue Market Share by Region (2020-2031)
 Figure 41. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
 Figure 42. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
 Figure 43. Europe Opioid-Induced Constipation Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 44. Europe Opioid-Induced Constipation Sales Market Share by Country (2020-2031)
 Figure 45. Europe Opioid-Induced Constipation Revenue Market Share by Country (2020-2031)
 Figure 46. Europe Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
 Figure 47. Europe Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
 Figure 48. Latin America Opioid-Induced Constipation Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 49. Latin America Opioid-Induced Constipation Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2020-2025)
 Figure 51. Latin America Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
 Figure 52. Latin America Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
 Figure 53. Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate 2020-2031 (US$ Million)
 Figure 54. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Country (2020-2031)
 Figure 56. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Type (2020-2025)
 Figure 57. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Application (2020-2025)
 Figure 58. Opioid-Induced Constipation Supply Chain (Upstream and Downstream Market)
 Figure 59. Global Production Market Share of Opioid-Induced Constipation Raw Materials by Region in 2024
 Figure 60. Opioid-Induced Constipation Distribution Channels
 Figure 61. Global Opioid-Induced Constipation Percentage 2020-2031: Indirect Sales VS Direct Sales
 Figure 62. Global Opioid-Induced Constipation Percentage 2020-2031: Online Sales VS Offline Sales
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$5900

This license allows only one user to access the PDF.
Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Opioid Induced Constipation OIC Drugs Market Research Report 2024
Global Opioid Induced Constipation Drugs Market Research Report 2024
Global Opioid Withdrawal Treatment Market Insights Forecast to 2030
Global Opioid Use Disorder Market Insights Forecast to 2030
Opioid Induced Side Effects Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chronic Idiopathic Constipation Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Constipation Treatment Drug Market Research Report 2025
Global Opioid Drugs Market Insights Forecast to 2030
Medical Devices Used For Opioid Use Disorder and Drug Addiction Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Gastrointestinal OTC Drugs Market Research Report 2024
Opioid Dependence Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Opioids Agonist Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Constipation Laxative Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Opioids Drug Market Research Report 2025
Global Opioid Use Disorder Treatment Market Research Report 2024
Global Chronic Idiopathic Constipation Drugs Market Research Report 2024
Global Opioid Narcotics Market Research Report 2024
Opioids Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Opioid Withdrawal Management Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Constipation Treatment Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions